AtriCure, Inc.

# AtriCure (ATRC) – New Deerfield Position Deerfield's $2.1M entry into AtriCure suggests conviction in the company's cardiac ablation and left atrial appendage (LAA) closure platforms, which address high-unmet-need arrhythmia markets. The timing likely reflects confidence in either near-term procedural volume recovery post-COVID, upcoming label expansions (particularly for the Isolator ablation system), or margin expansion from recent M&A integration. This is a relatively modest position size for Deerfield, suggesting opportunistic rather than thematic conviction.